Technical Analysis for DERM - Dermira, Inc.

Grade Last Price % Change Price Change
grade F 6.85 2.24% 0.15
DERM closed up 2.24 percent on Thursday, January 17, 2019, on 1.29 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical DERM trend table...

Date Alert Name Type % Chg
Jan 17 Doji - Bullish? Reversal 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 16 Wide Bands Range Expansion 2.24%
Jan 16 Down 3 Days in a Row Weakness 2.24%
Jan 15 Wide Bands Range Expansion 0.74%
Jan 14 1,2,3 Retracement Bearish Bearish Swing Setup -5.12%
Jan 14 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -5.12%
Jan 14 Wide Bands Range Expansion -5.12%
Jan 11 Inside Day Range Contraction -7.68%
Jan 11 Wide Bands Range Expansion -7.68%

Older signals for DERM ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company's late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04, a anticholinergic product that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage programs in preclinical development include DRM02, an inhibitor of phosphodiesterase-4 for the treatment of inflammatory skin diseases; and DRM05, a photodynamic therapy for the treatment of acne. Dermira, Inc. has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Is DERM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 31.42
52 Week Low 6.19
Average Volume 658,416
200-Day Moving Average 9.9615
50-Day Moving Average 9.416
20-Day Moving Average 7.325
10-Day Moving Average 7.181
Average True Range 0.5432
ADX 38.72
+DI 11.5429
-DI 31.5237
Chandelier Exit (Long, 3 ATRs ) 8.5004
Chandelier Exit (Short, 3 ATRs ) 7.8196
Upper Bollinger Band 8.575
Lower Bollinger Band 6.075
Percent B (%b) 0.31
BandWidth 34.129693
MACD Line -0.744
MACD Signal Line -0.8156
MACD Histogram 0.0716
Fundamentals Value
Market Cap 286.09 Million
Num Shares 41.8 Million
EPS -2.70
Price-to-Earnings (P/E) Ratio -2.54
Price-to-Sales 43.67
Price-to-Book 2.90
PEG Ratio -0.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.36
Resistance 3 (R3) 7.35 7.18 7.28
Resistance 2 (R2) 7.18 7.05 7.18 7.25
Resistance 1 (R1) 7.01 6.97 7.02 7.02 7.22
Pivot Point 6.84 6.84 6.84 6.84 6.84
Support 1 (S1) 6.67 6.71 6.68 6.68 6.48
Support 2 (S2) 6.50 6.63 6.50 6.45
Support 3 (S3) 6.33 6.50 6.43
Support 4 (S4) 6.34